Biota Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing oral, small molecule compounds to treat respiratory-related viral infections. The Company’s clinical-stage program is laninamivir octanoate, a long-acting neuraminidase inhibitor (NI). It is also engaged in developing BTA-798, also known as vapendavir, which is in Phase 2 for the treatment of human rhinovirus (HRV) infections in patients with moderate to severe asthma. The Company’s Zanamivir is marketed around the world by GlaxoSmithKline plc as Relenza for the prevention and treatment of Influenza A and B. Its Laninamivir Octanoate is marketed by Daiichi Sankyo as Inavir across Japan for the treatment of influenza A and B in adults and children. The lead product from the Company’s collaboration with Daiichi Sankyo for a new class of inhaled long acting NI’s is LANI, also known as CS-8958, which is marketed in Japan as Inavir for the treatment of influenza A and B infections.